AbolerIS Pharma
Katleen Swinnen, PhD, has a diverse background in the fields of biostatistics, pulmonary hypertension research, and clinical study coordination. Currently working at AbolerIS Pharma as a Project Manager, Katleen previously held roles as an R&D Manager at 2 Bridge and a Teaching Assistant at KU Leuven. With a Master's and PhD in Biomedical Sciences from KU Leuven, Katleen has also gained experience as a thesis student and student at Estee Lauder Companies.
This person is not in any offices
AbolerIS Pharma
AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells. IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.